hotspot -WSS

hotspot

author：Wikipedia 2025-09-28 00:50:30 - browse：59

The Johnson and Johnson booth at ESMO in Madrid. — The Johnson & Johnson booth at ESMO 2023. Andrew Joseph/STAT

MADRID — A competition has been brewing between two pharma titans — Johnson & Johnson and AstraZeneca — to gain an edge in the market for targeted lung cancer treatments. A primetime presentation here Monday amounted to the latest salvo.

At the annual meeting of the European Society for Medical Oncology, J&J unveiled three studies of its drug Rybrevant in different patient groups with non-small cell lung cancer with EGFR mutations. All were successful, with the drug, sometimes used in combination with other therapies, helping stave off progression of the disease.

In an interview, Mark Wildgust, J&J’s vice president of global medical affairs for oncology, framed the totality of the research as a case that Rybrevant could become a regularly used treatment for these patients.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Tesla recalling nearly 16,000 of its 2021

explore

WSS

Winning ticket for $1 billion Powerball jackpot sold in California

Stanford president's case begs question: Who takes blame?

Woman returns to dialysis after doctors remove transplanted pig kidney

Stanford president's case begs question: Who takes blame?

At ASCO, AstraZeneca reports strong data for breast cancer drug

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

hotspot

hotspot

explore

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Let's speed up science by embracing open access publishing

Guidelines to prevent youth baseball injuries need more muscle

Stanford president faces new allegations over 1999 paper

Trump demands the U.S. pay no more for drugs than other countries … again

Vir antibody drug aimed at influenza A fails in clinical trial

Virginia high school admissions case could be legal follow

Indian pharmaceutical industry in denial over drug

Heart attack and stroke risk calculators need revising

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

focus

NIH documents show early flaws of $1.6 billion long Covid program

How to increase colonoscopy rates? Looks like an AI can help

Letters to First Opinion on caregivers, digital health, and more

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

See how much Covid

Divers poised to search for children washed away in Pennsylvania flash flood

knowledge

entertainment

explore

focus